Feline Oral Squamous Cell Carcinoma

Feline oral squamous cell carcinoma (FOSCC) is the most commonly encountered malignant oral tumor in cats, arising from the squamous epithelium lining the oral cavity [1]. It is a highly locally invasive neoplasm that typically originates from the gingiva, tongue, sublingual region, or tonsillar areas, and is well known for its aggressive behavior and poor response to conventional therapies [1][3]. The etiology is considered multifactorial, with environmental exposures playing a significant role [5]. FOSCC also serves as a naturally occurring animal model for human head and neck squamous cell carcinoma (HNSCC), making it of broader biomedical interest [5].

Risk Factors

The etiology of FOSCC is considered multifactorial, with both environmental exposures and intrinsic tumor biological factors implicated [1][5]:

• ·Flea collar use: Cats wearing flea collars have been identified as having increased risk, likely due to chronic low-level exposure to organophosphate or pyrethrin-class insecticides concentrated near the oral/neck region [1][5].
• ·Dietary factors: Feeding canned food and canned tuna has been associated with elevated risk; this may relate to carcinogen exposure from certain preservatives, contaminants, or the can lining [1][5]. Cat foods containing certain additives or preparations have also been implicated in more recent epidemiological studies [5].
• ·Environmental tobacco smoke: Passive exposure to tobacco smoke has been identified as a risk factor, paralleling the well-established role of tobacco in human HNSCC [5].
• ·Other environmental exposures: Additional exposure categories under investigation include certain chemical compounds and dietary patterns, reflecting the known HNSCC risk profile in humans involving alcohol, areca nut, and high-risk papillomavirus [5].

Pathological Mechanism

FOSCC arises from malignant transformation of oral mucosal squamous epithelium. The tumor is characteristically locally invasive, with early destruction of underlying bone (mandibular or maxillary osteolysis), periosteum, and adjacent soft tissues [1]. Metastasis to regional lymph nodes (submandibular, retropharyngeal) can occur, though distant metastasis is less common at the time of diagnosis compared to the degree of local invasion.

At the cellular and molecular level, tumor-initiating cells (TICs) expressing CD44 and Bmi-1—markers also used in human HNSCC—have been identified in FOSCC. Elevated expression of these markers and alterations in telomere length and telomerase activity correlate inversely with treatment outcomes, suggesting that TICs contribute to tumor recurrence and therapeutic resistance [4].

The tumor microenvironment plays a key role in FOSCC progression. Histologic and immunohistochemical studies have demonstrated the presence of myxoid stroma within tumors, involving altered extracellular matrix components that may facilitate invasion [6]. Stromal remodeling and cancer-associated fibroblasts within this microenvironment are believed to support tumor progression.

Angiogenesis is a critical driver of FOSCC growth. Overexpression of angiogenic growth factors—including basic fibroblast growth factor (bFGF), vascular endothelial growth factor-C (VEGF-C), transforming growth factor-β (TGF-β), platelet-derived growth factor-A (PDGF-A), PDGF-C, and PDGF receptor-α (PDGFRα)—has been demonstrated in feline SCC tissue, highlighting their roles in tumor neovascularization and potential as therapeutic targets [7]. Additionally, polyamine pathway dysregulation has been identified; tumor tissues show elevated polyamine levels compared to normal oral mucosa, suggesting that polyamine biosynthesis contributes to tumor cell proliferation [8].

Clinical Examination

Diagnosis begins with a thorough oral examination, which often requires sedation or general anesthesia due to patient discomfort and the deep or inaccessible location of some tumors [1]. Characteristic findings include ulcerative or proliferative oral masses, bone lysis, loose teeth, and oral bleeding. Maxillary SCCs may present with facial deformity, nasal discharge, or orbital involvement, while sublingual and mandibular lesions often cause tongue immobility [1].

Histopathology and Cytology

Definitive diagnosis requires histopathological examination of a biopsy specimen. Incisional biopsy of the mass, with submission for routine hematoxylin and eosin (H&E) staining, is the gold standard. Cytological evaluation (fine-needle aspiration or impression smear) may be used as a preliminary step but cannot replace histopathology for definitive diagnosis or grading. Histologically, FOSCC exhibits islands or cords of malignant squamous cells with varying degrees of keratinization, pleomorphism, and stromal invasion [6].

Diagnostic Imaging

• ·Oral radiographs / dental radiographs: Reveal the extent of underlying bone lysis; essential for surgical planning.
• ·Computed tomography (CT) of the head and neck: Provides superior detail of bone involvement, tumor margins, and regional lymph node enlargement; strongly recommended for staging and treatment planning [1].
• ·Thoracic radiographs (3 views) or thoracic CT: To evaluate for pulmonary metastasis, though distant metastasis is less common.
• ·Abdominal ultrasound: Part of complete staging.

Regional Lymph Node Assessment

Fine-needle aspiration or biopsy of ipsilateral submandibular and retropharyngeal lymph nodes is recommended to assess for regional metastasis, as lymph node size alone is not a reliable indicator of involvement.

Laboratory Evaluation

While no laboratory findings are pathognomonic for FOSCC, baseline bloodwork is essential for staging, anesthetic risk assessment, and monitoring during therapy. Relevant findings may include:

• ·Complete Blood Count (CBC): Anemia (low HCT/PCV) may reflect chronic disease or oral hemorrhage; leukocytosis (elevated WBC) may indicate secondary infection or inflammatory response.
• ·Serum Chemistry Panel:
  • ·ALB (albumin): Hypoalbuminemia (low ALB) may reflect nutritional compromise from dysphagia and weight loss.
  • ·GLOB (globulins): May be elevated in the context of chronic inflammation or immune activation.
  • ·ALT: Typically normal unless hepatic involvement or drug-related hepatotoxicity is present.
  • ·BUN / CREA: Baseline renal function assessment is critical prior to platinum-based chemotherapy (e.g., carboplatin) and general anesthesia.
  • ·TBIL: Monitored as part of general hepatic health assessment.
  • ·PLT (platelets): Thrombocytopenia may occur with extensive neoplastic disease or bone marrow involvement.
• ·Urinalysis: Baseline assessment, particularly relevant prior to nephrotoxic chemotherapy.

Advanced Molecular Markers

Research studies have evaluated CD44 and Bmi-1 as putative tumor-initiating cell markers, as well as telomerase activity and telomere length, which correlate with prognosis [4]. These are currently research tools and not routinely used in clinical diagnosis.

Overview

Treatment of FOSCC is extremely challenging due to the tumor's locally invasive nature, proximity to critical anatomic structures, and frequently advanced stage at diagnosis. No single modality has consistently achieved long-term tumor control [3]. A multimodal approach is generally favored.

Surgery

Surgical excision (mandibulectomy or maxillectomy) with wide margins offers the best chance of local tumor control when the tumor is detected at an early stage and complete excision is anatomically feasible. However, most cats present with advanced disease, limiting the possibility of curative-intent resection. Rostral mandibulectomy carries a more favorable functional outcome than caudal or total mandibulectomy.

Radiation Therapy

Radiation therapy (RT) is a recognized treatment option for FOSCC, particularly when surgery is not feasible or for post-operative control of microscopic disease [3]. Accelerated radiation protocols (delivering higher doses per fraction over a shorter overall treatment time) combined with carboplatin (a platinum-based chemosensitizer) have been evaluated. In a recent study combining accelerated RT with carboplatin, with or without subsequent toceranib phosphate, median survival times remained limited, but the combination approach demonstrated some biologic activity against FOSCC [3]. Local tumor control remains difficult to achieve even with RT [3].

Chemotherapy

• ·Carboplatin: Most commonly used platinum compound in FOSCC; administered in combination with RT as a radiosensitizer [3]. Renal function must be carefully monitored given nephrotoxic potential.
• ·Cisplatin: Contraindicated in cats due to severe, potentially fatal pulmonary toxicity.
• ·DFMO (2-difluoromethylornithine): A polyamine inhibitor evaluated in a proof-of-concept study; DFMO was administered orally to cats with histologically confirmed oral SCC and was shown to reduce polyamine levels in tumor tissue compared to normal mucosa. The drug was generally tolerated, with gastrointestinal, dermatologic, auditory, hematological, and biochemical parameters monitored [8]. Further clinical evaluation is needed.

Targeted Therapy

• ·Toceranib phosphate (Palladia): A receptor tyrosine kinase inhibitor (targeting VEGFR, PDGFR, Kit) that has shown biologic activity against FOSCC. Given the known overexpression of VEGF-C, PDGF-A, PDGF-C, and PDGFRα in feline SCC [7], toceranib represents a rational targeted approach. It has been used as a follow-up to RT/carboplatin in clinical trials [3].

Supportive Care

Given the severe impact of FOSCC on eating and quality of life, supportive care is an essential component of management:

• ·Esophagostomy or gastrostomy tube placement: Critical for nutritional support in cats unable to eat voluntarily; helps maintain body weight and supports recovery during treatment.
• ·Analgesic therapy: Opioids (e.g., buprenorphine), NSAIDs (with caution and renal monitoring), and gabapentin for neuropathic pain.
• ·Antibiotics: For secondary oral infections and tumor-associated septic stomatitis.
• ·Anti-emetics and appetite stimulants: To address nausea related to chemotherapy or RT.
• ·Oral hygiene measures: Chlorhexidine rinses to reduce bacterial load in the tumor microenvironment.

Palliative Care

For cats with advanced, unresectable disease, palliative intent—focused on pain management, nutritional support, and maintenance of quality of life—may be the most appropriate and humane approach.

FOSCC carries an extremely poor prognosis, and this must be communicated clearly and compassionately to owners at the time of diagnosis [1][3][4].

Key Prognostic Statistics

• ·Overall median survival time for cats with oral SCC treated with various modalities is typically reported as less than 2–3 months from diagnosis, with many cats succumbing to disease within weeks if untreated or if treatment fails.
• ·Even with aggressive multimodal therapy (surgery, radiation, chemotherapy), long-term tumor control is rarely achieved [3].
• ·In a study evaluating accelerated RT combined with carboplatin, with or without toceranib phosphate follow-up, meaningful tumor control was demonstrated in a subset of patients, but overall survival remained short, underscoring the difficulty in managing this disease [3].
• ·Stereotactic radiation therapy (SRT) studies have shown some individual cats achieving longer survivals, but the overall population outcomes remain poor [4].

Prognostic Factors

• ·Tumor location: Sublingual and caudal oral tumors carry a worse prognosis than rostral tumors due to earlier functional compromise and reduced surgical accessibility [1].
• ·Stage at diagnosis: Advanced bone involvement significantly worsens prognosis.
• ·Tumor-initiating cell markers: Higher expression of CD44 and Bmi-1, longer telomere lengths in TICs, and elevated telomerase activity were inversely correlated with treatment outcomes in an SRT-treated cohort — cats with these features had significantly shorter survival times [4].
• ·Myxoid stromal content: The presence of extensive myxoid stroma in FOSCC may be associated with more aggressive tumor behavior through altered microenvironmental signaling [6].
• ·Response to initial treatment: Cats achieving an objective tumor response to RT or combined therapy have improved survival compared to non-responders.

Quality of Life Considerations

Given the dismal prognosis, quality of life assessment is central to all treatment decisions. Many owners elect euthanasia upon disease progression due to the profound impact of dysphagia, pain, and weight loss on the cat's daily comfort.

There is currently no vaccine available for FOSCC. However, given the identified environmental risk factors, the following preventive measures are clinically relevant and should be discussed with cat owners [1][5]:

• ·Avoid flea collar use: Flea collars have been identified as a risk factor for FOSCC [1][5]. Owners should be counseled to use alternative flea prevention methods (e.g., topical or oral veterinary-approved parasiticides) rather than flea collars, particularly for cats with long-term continuous use.
• ·Dietary modification: Limiting or reducing the frequency of feeding canned tuna and excessive quantities of certain canned cat foods may be prudent, given the epidemiological associations identified [1][5]. A varied, balanced diet is advisable.
• ·Reduction of environmental tobacco smoke exposure: Cats living in households where occupants smoke are at increased risk [5]. Eliminating or minimizing indoor tobacco smoke exposure is recommended.
• ·Regular oral examinations: Routine annual (or more frequent) veterinary oral examinations allow for early detection of suspicious lesions. Early-stage detection, while not preventing SCC, improves the likelihood of obtaining cleaner surgical margins and potentially better outcomes.
• ·Owner education on oral health monitoring: Educating owners to watch for early warning signs—persistent oral ulcers, bleeding gums, excessive drooling, difficulty eating, or foul breath—can prompt earlier veterinary evaluation.
• ·Monitoring of ongoing research: Epidemiological studies are actively investigating additional environmental and dietary risk factors [5], and new findings may expand preventive recommendations in the future.